4//SEC Filing
Bruno Lawrence 4
Accession 0000950170-24-001227
CIK 0001958086other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 5:40 PM ET
Size
8.6 KB
Accession
0000950170-24-001227
Insider Transaction Report
Form 4
Bruno Lawrence
DirectorChairman and CEO
Transactions
- Tax Payment
Common Stock
2023-12-31$17.66/sh−38,473$679,433→ 164,103 total - Exercise/Conversion
Performance Shares
2023-12-31−100,058→ 0 totalExercise: $0.00→ Common Stock (100,058 underlying) - Exercise/Conversion
Common Stock
2023-12-31+100,058→ 202,576 total
Footnotes (1)
- [F1]These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021. The Company finished in the 81st percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2023. Excess shares that could vest above the 75th percentile are subject to an absolute total shareholder return modifier, which was negative over the relevant performance period, thereby reducing the number of such shares eligible to vest by one-half. Therefore, the performance criteria and requirements for vesting have been satisfied at 106.25% of the target award level, and such number of shares vested on December 31, 2023.
Documents
Issuer
Core Laboratories Inc. /DE/
CIK 0001958086
Entity typeother
Related Parties
1- filerCIK 0001730336
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 5:40 PM ET
- Size
- 8.6 KB